Patent ID: 8293481

Claim:
A method for evaluating the prognosis of a subject with a chronic disease where there is vascular dysfunction, comprising providing a biological sample from said subject, performing an ELISA to measure in said biological sample the expression level of TAO kinase I, glutaminase 2 (Gls2), v-raf-1 murine leukemia viral oncogene homolog 1 (Raf1), or bile acid-Coenzyme A amino acid N-acyltransferase (Baat), and classifying the prognosis of the subject as favorable if the expression level of TAO kinase I, Gls2, Raf1, or Baat in the biological sample is less than a control expression level of TAO kinase I, Gls2, Raf1, or Baat, or classifying the prognosis of the subject as poor if the expression level of TAO kinase I, Gls2, Raf1, or Baat in the biological sample is not less than the control expression level of TAO kinase I, Gls2, Raf1, or Baat and wherein the control expression level is an expression level in a biological sample from a normal subject, a standard expression level in biological samples from a population of normal subjects, or a previously determined expression level in a biological sample from the subject.